

Evidence synthesis and development of economic models



CLIENT SITUATION

A medium-sized biotechnology company was developing a biologic therapy for an oncology indication and needed support with their market access strategy, which included developing a value proposition, GVD, and economic models to inform HTA submissions in 12 countries.

PRMA CONSULTING SOLUTION

Comprehensive evidence review and synthesis, meeting the most stringent HTA requirements

- A systematic review identified all available information on efficacy, safety, PROs, and costs.
- A meta-analysis of the efficacy data was undertaken in accordance with HTA guidelines.

Evidence generation to provide data that were not available from the trial program or literature

- An epidemiology study established the size of the eligible patient population.
- Further research identified the burden of disease and unmet need in terms of premature mortality and years of life lost, as well as the real-world healthcare resource use and cost of treatment.
- Preference elicitation studies generated health state utility values for use in the economic models.
- Cost-effectiveness and budget impact models were developed such that they could be adapted for multiple countries, and were validated by payers and key opinion leaders in an advisory board.

The client's market access strategy was optimized

- A range of potential comparators were identified for inclusion in the economic models.
- Insight into changing treatment patterns helped to position the new treatment in the context of clinical practice in each country.
- A poster of key results was presented at an ASCO meeting, highlighting the scientific value of the research.



Please let your staff who supported us know how appreciative we are of their efforts. From the advisory boards to the GVD development to the modeling efforts and numerous projects, the support and partnership was great.

Therapeutic Area Head, Oncology

Visit our website >>

+44 (0)1252 786284
info@prmaconsulting.com

